Compare JetBlue Airways Corporation (JBLU) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs Medtronic PLC — how do they compare? JetBlue Airways Corporation trades at $5.38 (market cap $2.03B), while Medtronic PLC trades at $82.59 (market cap $106.61B). The key difference: Medtronic PLC is far larger — about 52.5× JetBlue Airways Corporation's market cap, and Medtronic PLC pays a 3.46% dividend while JetBlue Airways Corporation pays none. Which is the better fit depends on your goals.
| JBLU | MDT | |
|---|---|---|
Market Cap | $2.03B | $106.61B |
Sector | Industrials | Health |
52-Week High | $6.46 | $105.35 |
52-Week Low | $4.03 | $73.75 |
Enterprise Value | $9.19B | $125.36B |
Dividend Yield | — | 3.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $5.45, up 0.55% today, with technical indicators showing a neutral bias despite recent earnings misses. The airline reported a net loss of $602 million in 2025 with negative profit margins, though valuation metrics like P/S of 0.22 appear attractive. Recent news highlights expansion at Fort Lauderdale and new payment partnerships, while analyst consensus remains cautious with a $5.12 price target.
JBLU faces significant challenges with persistent losses and high debt levels, though strategic expansions and cost management efforts provide some optimism. The stock trades near analyst targets with mixed sentiment, requiring careful monitoring of upcoming Q2 2026 earnings and fuel cost trends for directional clarity.
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
